(NRO) Neurones - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0004050250
NRO: Infrastructure Management, Application Development, Consulting Services
Neurones S.A. (PA:NRO) is a France-based IT services company with a market cap of 1.15B EUR, operating at a P/E of 23.82. Established in 1984, the firm has built a robust presence in IT consulting and related services, serving a diverse range of industries including banking, healthcare, telecom, and the public sector. Its offerings span infrastructure management, application development, and consulting, with a strong focus on digital transformation.
The companys infrastructure services include cloud management, cybersecurity, and IT operations, while its application services cover SAP, digital solutions, and robotic process automation. Consulting services extend to digital transformation, agile methodologies, and emerging technologies like AI, blockchain, and IoT. This broad service portfolio positions Neurones as a one-stop-shop for businesses undergoing digital transformation.
From an investment perspective, Neurones operates in a growing sector with a P/S ratio of 1.48, indicating reasonable revenue scalability. Its diversified client base across industries reduces dependency on any single market, while its focus on cloud, cybersecurity, and automation aligns with long-term tech trends. However, with a P/B ratio of 3.27, investors may want to assess whether the companys growth prospects justify its valuation.
Additional Sources for NRO Stock
NRO Stock Overview
| Market Cap in USD | 1,254m |
| Sector | Technology |
| Industry | Information Technology Services |
| GiC Sub-Industry | IT Consulting & Other Services |
| IPO / Inception |
NRO Stock Ratings
| Growth 5y | 84.2% |
| Fundamental | 53.3% |
| Dividend | 61.4% |
| Rel. Strength | 7.92 |
| Analysts | - |
| Fair Price Momentum | 54.95 EUR |
| Fair Price DCF | 60.94 EUR |
NRO Dividends
| Dividend Yield 12m | 2.58% |
| Yield on Cost 5y | 7.29% |
| Annual Growth 5y | 43.10% |
| Payout Consistency | 89.2% |
NRO Growth Ratios
| Growth Correlation 3m | 85.7% |
| Growth Correlation 12m | 38.1% |
| Growth Correlation 5y | 96.3% |
| CAGR 5y | 23.50% |
| CAGR/Max DD 5y | 1.10 |
| Sharpe Ratio 12m | -0.19 |
| Alpha | 1.69 |
| Beta | 0.579 |
| Volatility | 30.15% |
| Current Volume | 2.7k |
| Average Volume 20d | 3.9k |
As of March 30, 2025, the stock is trading at EUR 48.45 with a total of 2,730 shares traded.
Over the past week, the price has changed by -1.22%, over one month by -1.32%, over three months by +11.76% and over the past year by +8.43%.
Partly, yes. Based on ValueRay Fundamental Analyses, Neurones (PA:NRO) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 53.25 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NRO as of March 2025 is 54.95. This means that NRO is currently undervalued and has a potential upside of +13.42% (Margin of Safety).
Neurones has no consensus analysts rating.
According to ValueRays Forecast Model, NRO Neurones will be worth about 59.4 in March 2026. The stock is currently trading at 48.45. This means that the stock has a potential upside of +22.64%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 60 | 23.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 59.4 | 22.6% |